Next-generation sequencing of advanced urothelial bladder cancers has revealed a diverse spectrum of actionable genomic alterations in 83% of cases, including HER2 mutations in 6% of tumours [11]. This evidence concerns the gene ERBB2 and bladder transitional cell carcinoma.